PF-07220060

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerAdvanced or Metastatic Solid TumorsESSLiposarcoma

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

PF-07220060

Pfizer

Phase 3

52

Adenocard

Astellas

Preclinical

23

Methylthioninium Chloride

PProvepharm SAS

Preclinical

34

Tianeptine

Pfizer

Preclinical

15

Ablavar

LLantheus Medical Imaging

Preclinical

26

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

17

Naltrexone/bupropion

Novo Nordisk

Preclinical

18

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

19

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

110

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer5 trials

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Recruiting·Pfizer·Phase 3·NCT06760637·1,020 enrolled

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Active, not recruiting·Pfizer·Phase 1/2·NCT06206837·71 enrolled

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Recruiting·Relay Therapeutics·Phase 1·NCT05216432·930 enrolled

Show 2 more trials

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active, not recruiting·Pfizer·Preclinical·NCT05262400·235 enrolled

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Completed·Pfizer·Phase 2·NCT06465368·121 enrolled

CAR1 trial

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Completed·Pfizer·Phase 1·NCT06897683·14 enrolled

ESS1 trial

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Recruiting·Pfizer·Phase 1·NCT07160738·28 enrolled

Adult1 trial

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Completed·Pfizer·Phase 1·NCT06267963·12 enrolled

Advanced or Metastatic Solid Tumors1 trial

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Recruiting·Pfizer·Phase 1·NCT04606446·320 enrolled

3 more indications

ART1 trial

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

Completed·Pfizer·Phase 1·NCT07130097·35 enrolled

Liposarcoma1 trial

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active, not recruiting·BBlueprint Medicines·Phase 2·NCT04557449·362 enrolled

Advanced or Metastatic Breast Cancer1 trial

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)

Active, not recruiting·Pfizer·Phase 2·NCT06105632·333 enrolled

Details

Drug Info

Related News